ArticleScientific reports2026
In vitro experiments and bioinformatic analyses implicate KAT2A in the occurrence and development of hepatocellular carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Hepatocellular carcinoma (LIHC) is a major global health concern, ranking as the sixth most common cancer and the fourth leading cause of cancer-related mortality worldwide, highlighting the urgent need to develop reliable diagnostic tools, biomarkers, and therapeutic targets to improve early detection and reduce mortality; KAT2A, a histone lysine acetyltransferase, plays crucial roles in multiple biological processes including chromatin remodeling, transcriptional regulation, cell cycle control, and apoptosis initiation, yet its specific role in the initiation and progression of hepatocellular carcinoma remains poorly understood; in this study, we assessed KAT2A expression levels in liver hepatocellular carcinoma tissues using data from the TCGA database and further analyzed its association with immune cell infiltration through single-cell data analysis, followed by evaluating the relationship between KAT2A and patient prognosis using Kaplan–Meier survival analysis combined with Cox regression modeling, while also exploring its potential biological functions via Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses, and finally validating the impact of KAT2A on the proliferation and migration of hepatocellular carcinoma cells through in vitro experiments; our findings revealed that KAT2A is significantly upregulated in LIHC tissues and plays a key role in promoting the proliferation and migration of LIHC cells, suggesting that KAT2A may serve as a novel prognostic biomarker and a promising therapeutic target for immunotherapy in hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.